2-methoxy-5,6,7,8-tetrahydronaphthoic acid | 60346-40-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 2-methoxy-5,6,7,8-tetrahydronaphthoic acid
• 英文别名: 2-methoxy-5,6,7,8-tetrahydro-[1]naphthoic acid；2-Methoxy-5,6,7,8-tetrahydro-[1]naphthoesaeure；2-methoxy-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid；5,6,7,8-tetrahydro-2-methoxy-1-naphthalenecarboxylic acid；5.6.7.8-Tetrahydro-2-methoxy-1-naphthoesaeure；6-Methoxytetralin-5-carboxylic acid；2-methoxy-5,6,7,8-tetrahydronaphthalene-1-carboxylic acid
• CAS: 60346-40-9
• 化学式: C₁₂H₁₄O₃
• 分子量: 206.241
• InChiKey: XCCRLEOPTMKRRF-UHFFFAOYSA-N

物化性质

• 熔点：
  148-150 °C
• 沸点：
  368.4±42.0 °C(Predicted)
• 密度：
  1.193±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-methoxy-5,6,7,8-tetrahydronaphthoic acid 在 三氯化铝 、 苯 作用下， 生成 2-羟基-5,6,7,8-四氢化萘-1-羧酸甲酯
  参考文献：
  名称：

  The Determination of Double-bond Character in Cyclic Systems. IV. Tetrahydronaphthalene. Steric Facilitation of Chelation¹

  摘要：

  DOI：

  10.1021/ja01546a028
• 作为产物：
  描述：

  2-甲氧基-1-萘甲酸 在 钯 水 作用下， 以 溶剂黄146 为溶剂， 反应 23.0h， 以to give product as a yellow solid (0.377 g, 37%)的产率得到2-methoxy-5,6,7,8-tetrahydronaphthoic acid
  参考文献：
  名称：

  N-(2-phenyl-4-piperidinybutyl)-5,6,7,8-tetrahydro-1-naphthalenecarboxamides and their use as neurokinin 1 (NK1) and/or neurokinin 2 (NK2) receptor antagonists

  摘要：

  式(I)的化合物，其中R2是5,6,7,8-四氢萘-1-基基团，该基团可以被取代（其余在此定义的基团），以及含有该化合物的制药组合物和使用该化合物治疗拮抗NK1和/或NK2受体有益的疾病的方法。

  公开号：

  US06403601B1

文献信息

• N-(2-phenyl-4-piperidinybutyl)-5,6,7,8-tetrahydro-1-naphthalenecarboxamides and their use as neurokinin 1 (NK1) and/or neurokinin 2 (NK2) receptor antagonists
  申请人：Astrazeneca AB

  公开号：US06403601B1

  公开（公告）日：2002-06-11

  Compounds of formula (I), wherein R2 is a 5,6,7,8-tetrahydronaphth-1-yl group which may be substituted (the remaining groups defined herein), and pharmaceutical compositions containing the compounds and methods of using the compounds in the treatment of a condition where antagonism of the NK1 and/or NK2 receptors is beneficial.

  式（I）的化合物，其中R2是一个可以被取代的5,6,7,8-四氢萘基团（在此定义的其余基团），以及含有这些化合物的药物组合物和使用这些化合物治疗NK1和/或NK2受体拮抗有益的方法。
• Tricyclic 5-HT.sub.3 receptor antagonists
  申请人：Syntex (U.S.A.) Inc.

  公开号：US05202333A1

  公开（公告）日：1993-04-13

  The present invention is directed to 5-HT.sub.3 receptor antagonist compounds of formula I: ##STR1## in which the dashed line denotes an optional double bond; n is 1, 2 or 3; p is 0, 1, 2 or 3; q is 0, 1 or 2; each R.sup.1 is independently selected from halogen, hydroxy, lower alkoxy, lower alkyl, nitro, amino, amino carbonyl, (lower alkyl)amino, di(lower alkyl)amino, and (lower alkanoyl)amino; each R.sup.2 is lower alkyl; and R.sup.3 is a group selected from Formulae (a), (b), (c) and (d): ##STR2## in which u is 0 or 1; z is 1, 2 or 3; and R.sup.4 is C.sub.1-7 alkyl, C.sub.3-8 cycloalkyl, C.sub.3-8 cycloalkyl-C.sub.1-2 alkyl, or a group (CH.sub.2).sub.t R.sup.5 where t is 1 or 2 and R.sup.5 is thienyl, pyrrolyl, or furyl, each optionally further substituted by one or two substituents selected from C.sub.1-6 alkyl, C.sub.1-6 alkoxy, trifluoromethyl or halogen, or is phenyl optionally substituted by one or two substituents selected from C.sub.1-4 alkoxy, trifluoromethyl, halogen, nitro, carboxy, esterified carboxy, and C.sub.1-4 alkyl optionally substituted by hydroxy, C.sub.1-4 alkoxy, carboxy, esterified carboxy or in vivo hydrolyzable acyloxy; and the pharmaceutically acceptable salts, individual isomers, mixtures of isomers, processes for preparation, compositions, and methods of use thereof.

  本发明涉及式I的5-HT.sub.3受体拮抗剂化合物：##STR1## 其中虚线表示可选的双键；n为1、2或3；p为0、1、2或3；q为0、1或2；每个R.sup.1是独立选择的卤素、羟基、较低的烷氧基、较低的烷基、硝基、氨基、氨基羰基、（较低的烷基）氨基、二（较低的烷基）氨基和（较低的酰基）氨基；每个R.sup.2是较低的烷基；R.sup.3是从式（a）、（b）、（c）和（d）中选择的一组：##STR2## 其中u为0或1；z为1、2或3；R.sup.4为C.sub.1-7烷基、C.sub.3-8环烷基、C.sub.3-8环烷基-C.sub.1-2烷基或（CH.sub.2）.sub.tR.sup.5，其中t为1或2，R.sup.5为噻吩基、吡咯基或呋喃基，每个都可以进一步被选择自C.sub.1-6烷基、C.sub.1-6烷氧基、三氟甲基或卤素的一个或两个取代基取代，或是苯基，可选地被一个或两个选择自C.sub.1-4烷氧基、三氟甲基、卤素、硝基、羧基、酯化羧基和C.sub.1-4烷基的取代基取代，可选地被羟基、C.sub.1-4烷氧基、羧基、酯化羧基或在体内可水解的酰氧基取代的C.sub.1-4烷基；以及其药学上可接受的盐、单个异构体、异构体混合物、制备方法、组合物和使用方法。
• [EN] NOVEL THREE-RING FUSED STRUCTURE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF<br/>[FR] NOUVEAU COMPOSÉ DE STRUCTURE À TROIS CYCLES CONDENSÉS, SON PROCÉDÉ DE PRÉPARATION ET UTILISATION ASSOCIÉE<br/>[ZH] 一种新颖的三并环结构化合物及其制备方法和用途
  申请人：INNOVENT BIOLOGICS SUZHOU CO LTD

  公开号：WO2020119592A1

  公开（公告）日：2020-06-18

  本发明属于药物化学领域，公开了一种三并环结构化合物及其制备方法和用途。本发明的化合物可以作为PI3K-γ选择性抑制剂，具有抗肿瘤、抗神经退行性疾病(如阿尔茨海默病)、抗炎、抗病毒、抗多发性硬化症、免疫调节等多种药理活性。
• 2-(Quinuclidin-3-yl)pyrido[4,3-b]indol-1-ones and isoquinolin-1-ones. Potent conformationally restricted 5-HT3 receptor antagonists
  作者：Robin D. Clark、Aaron B. Miller、Jacob Berger、David B. Repke、Klaus K. Weinhardt、Bruce A. Kowalczyk、Richard M. Eglen、Douglas W. Bonhaus、Chi Ho Lee

  DOI：10.1021/jm00070a008

  日期：1993.9

  Several series of N-(quinuclidin-3-yl)aryl and heteroaryl-fused pyridones were synthesized and evaluated for 5-HT3 receptor affinity. In the heteroaryl series, 2-(quinuclidin-3-yl)tetrahydropyrido-[4,3-b]indol-1-one (8a) and the 4,5-alkano-bridged analogues (14 and 15) displayed high 5-HT3 receptor affinity with pK(i) values > 9. The (3S)-quinuclidinyl isomers had > 10 fold higher affinity than the (3R)-isomers. In a series of 2-quinuclidin-3-yl)isoquinolin-1-ones, derivatives substituted with small lipophilic groups (25b-e) and with 4,5-alkano-bridges (34-36) also displayed high affinity. In particular, the hexahydro-1H-benz[de]isoquinolinone (S,S)-37 was the highest affinity 5-HT3 receptor ligand prepared (pK(i) 10.4). A number of the high affinity ligands were shown to be potent 5-HT3 receptor antagonists in vivo as determined by inhibition of the B-J reflex in the anesthetized rat. Again, (S,S)-37 was the most active agent tested (ID50 0.02 mug/kg iv), and this compound was also potent in blocking cisplatin-induced emesis in both the ferret and the dog. Computer modeling studies were performed, and previously reported 5-HT3 receptor antagonist pharmacophore models were refined to include a key lipophilic binding domain.
• The Reimer—Tiemann Reaction of β-Tetralol
  作者：Richard T. Arnold、Harold E. Zaugg、Joseph Sprung

  DOI：10.1021/ja01850a048

  日期：1941.5